



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 35/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/JP2024/080220

(22) International Filing Date:

06 December 2024 (06.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/JP2023/044950

08 December 2023 (08.12.2023) JP

(71) Applicant: **ASTELLAS PHARMA INC.** [JP/JP]; 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411 (JP).

(72) Inventors: **NAKANO, Kazue**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP). **NAKAZAWA, Taisuke**; c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 1038411 (JP).

(74) Agent: **YAMAMOTO, Osamu** et al.; YUASA AND HARA, Section 206, Shin-Otemachi Bldg., 2-1, Otemachi 2-chome, Chiyoda-ku, Tokyo, 100-0004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND ANTI-VEGFR2 ANTIBODIES

(57) Abstract: The present invention provides a combination therapy involving bispecific binding agents comprising two binding domains binding to CLDN18.2 and a binding domain binding to CD3 and antibodies that binds to VEGFR2. The combination therapy is effective in treating cancer involving cancer cells expressing CLDN18.2.

WO 2025/121444 A1